News & Updates
Filter by Specialty:
DPP-4–to–SGLT2 inhibitor switch confers multiple benefits for patients with diabetes, hypertension
In the treatment of patients with type 2 diabetes mellitus and hypertension, switching from a dipeptidyl peptidase-4 (DPP-4) inhibitor to the sodium-glucose cotransporter-2 (SGLT2) inhibitor luseogliflozin appears to have favourable effects on blood pressure (BP), circadian rhythm, and night-time systolic BP (SBP) and pulse rate (PR), according to data from the open-label LUNA trial.
DPP-4–to–SGLT2 inhibitor switch confers multiple benefits for patients with diabetes, hypertension
28 Sep 2021
NSAIDs: suitable prophylaxis after cataract surgery?
The addition of corticosteroids (ie, prednisolone) to NSAID eyedrops (ie, ketorolac) did not provide additional benefit relative to ketorolac alone or dropless surgery using a sub-Tenon capsule depot as an anti-inflammatory prophylactic regimen to prevent postoperative central macular thickening following uncomplicated cataract surgery, a Danish study suggests.
NSAIDs: suitable prophylaxis after cataract surgery?
28 Sep 2021
Mepolizumab benefits held up over time
Beyond 1 year, the humanized monoclonal antibody mepolizumab maintained real-world efficacy and safety in patients with severe eosinophilic asthma in the REALITI-A cohort study, reports an expert at ERS 2021.